comparemela.com

Page 2 - Jingye Zhou News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Eccogene Raises CNY 180 Million in Series B Equity Financing, Propelling its Pipeline of Treatments for Metabolic Diseases

/PRNewswire/ Eccogene Inc., a clinical-stage biotechnology company developing innovative therapeutic solutions for metabolic diseases, today announced a CNY.

United statesJingye zhouEccogene incValliance capitalNew alliance capitalZhangjiang healthcare ventureRockbleu capitalYufu investmentHuajin capitalElikon ventureDelos capitalOriza seed capitalChief executive officer

Eccogene Raises CNY 180M in Series B Equity Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Jingye zhouValliance capitalSeriesb equityNew alliance capitalZhangjiang healthcare ventureRockbleu capitalYufu investmentHuajin capitalElikon ventureDelos capitalOriza seed capital

Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004

/PRNewswire/ Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence a.

United statesJingye zhouDrug administration

Eccogene Announces US IND Approval for THRβ agonist ECC4703

/PRNewswire/ Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence.

Prnewswire eccogeneJingye zhouDrug administration

Eccogene announces the addition of Jacques Mizrahi, PhD to Scientific Advisory Board

Eccogene announces the addition of Jacques Mizrahi, PhD to Scientific Advisory Board
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Jacques mizrahiJingye zhouVenture capitalInserm transfertParis franceதுணிகர மூலதனம்பாரிஸ் பிரான்ஸ்

vimarsana © 2020. All Rights Reserved.